EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer



Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer



Clinical Breast Cancer 9(3): 178-183



The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC). Forty-one women with HER2+ MBC were treated with gemcitabine 1000 mg/m(2) intravenously (I.V.) days 1, 8, and 15 and trastuzumab 4-mg/kg I.V. loading dose and then 2 mg/kg weekly. Cycles were repeated every 28 days. Patients were evaluated after 8 weeks of treatment; responders/stable patients continued treatment until progression. Patients received a median of 28 weeks of treatment. Eleven of 37 evaluable patients (30%; 95% CI, 17%-46%) had major responses. The median progression-free survival (PFS) was 4 months (95% CI, 1.9-5.3 months), with a 1-year PFS of 17%. Four of 15 patients (27%) who had previously received trastuzumab for MBC had partial responses. The gemcitabine/trastuzumab combination was well tolerated. The combination of gemcitabine and trastuzumab is an active regimen but appears less active than trastuzumab in combination with either taxanes or vinorelbine. The role of gemcitabine/trastuzumab (versus gemcitabine alone) in women who have already received a trastuzumab-containing regimen for HER2+ MBC is not defined by this study.

(PDF emailed within 0-6 h: $19.90)

Accession: 056909658

Download citation: RISBibTeXText

PMID: 19661042

DOI: 10.3816/CBC.2009.n.029



Related references

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1003-1003, 2016

Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. Clinical Breast Cancer 4 Suppl 3: S117-S120, 2004

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. Journal of Korean Medical Science 24(5): 910-917, 2010

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1057-1057, 2016

Phase II study of weekly intravenous trastuzumab in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology 26(4 SUPPL 12): 78-83, 1999

Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). Journal of Clinical Oncology 24(18_suppl): 10730-10730, 2016

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series. Journal of Oncology 2012: 198412-198412, 2012

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology 26(4 Suppl 12): 78-83, 1999

High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clinical Oncology ()) 17(8): 630-635, 2005

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer 90(1): 36-40, 2004

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy. Journal of Clinical Oncology 26(15_suppl): 1053-1053, 2016

Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 32(3): 335-339, 2005

Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer. Journal of Clinical Oncology 23(16_suppl): 704-704, 2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet. Oncology 17(3): 357-366, 2016

Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 23(16_suppl): 803-803, 2016